Adolescents and HIV infection

Current Opinion in HIV and AIDS

Volumn 2, Issue 5, 2007, Pages 431-436

  Foster, Caroline ^a   Waelbrouck, Anne ^b   Peltier, Alexandra ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c Project 107 Lux Development   (Rwanda)

Author keywords

Adherence; HIV infection; Teenager

Indexed keywords

ANTIRETROVIRUS AGENT; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENCE; CONDOM; CONTRACEPTION; DYSLIPIDEMIA; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; LIPODYSTROPHY; PATIENT CARE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; STIGMA; SUPPORT GROUP; TEAMWORK; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 34547881961     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282ced150     Document Type: Review

References (43)

1. Thorne C, Newell ML, Botet FA, et al. Older children and adolescents surviving with vertically acquired HIV infection. J Acquir Immune Defic Syndr 2002; 29:396-401.
2. Suris JC, Parera N. Sex, drugs and chronic illness: health behaviours among chronically ill youth. Eur J Public Health 2005; 15:484-488.
3. Brown LK, Schultz JR, Parsons JT, et al. Sexual behavior change among human immunodeficiency virus-infected adolescents with hemophilia. Adolescent Hemophilia Behavioral Intervention Evaluation Project Study Group. Pediatrics 2000; 106:E22.
4. Olley BO, Seedat S, Stein DJ, et al. Self-disclosure of HIV serostatus in recently diagnosed patients with HIV in South Africa. Afr J Reprod Health 2004; 8:71-76.
5. Forsberg AD, King G, Delaronde SR, et al. Maintaining safer sex behaviours in HIV-infected adolescents with haemophilia. The Hemophilia Behavioral Evaluative Intervention Project Committee. J Acquir Immune Defic Syndr 2002; 29:302-309.
6. Dave SS, Stephenson J, Mercey DE, et al. Sexual behaviour, condom use, and disclosure of HIV status in HIV infected heterosexual individuals attending an inner London HIV clinic. Sex Transm Infect 2006; 82:117-119.
7. Crosby RA, Yarber WL, Sanders SA, et al. Men with broken condoms: who and why? Sex Transm Infect 2007; 83:71-75.
8. Merchant RC, Keshavarz R. Human immunodeficiency virus postexposure prophylaxis for adolescents and children. Pediatrics 2001; 108:E38.
9. Havens PL. American Academy of Pediatrics Committee on Pediatric AIDS. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003; 111 (6 Pt 1):1475-1489.
10. Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007; 97:1047-1052.
11. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81:222-227.
12. Belzer M, Rogers AS, Camarca M, et al. Contraceptive choices in HIV infected and HIV at risk adolescent females. J Adolesc Health 2001; 29 (3 suppl): 93-100.
13. Cohn SE, Park JG, Watts DH, et al., the ACTG A 5093 protocol team. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81:222-227.
14. Levin L, Henry-Reid L, Murphy DA, et al. Incident pregnancy rates in HIV infected and HIV uninfected at-risk adolescents. J Adolesc Health 2001; 29 (3 Suppl):101-108.
15. Aaron E, Levine AB. Gynecologic care and family planning for HIV infected women. AIDS Read 2005; 15:426.
16. Sturdevant MS, Belzer M, Weissman G, et al. The relationship of unsafe sexual behavior and the characteristics of sexual partners of HIV infected and HIV uninfected adolescent females. J Adolesc Health 2001; 29 (3 Suppl):64-71.
17. Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000; 154:127-134.
18. Markowitz LE, Dunne EF, Saraiya M. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-2):1-24.
19. Buchacz K, Rogol AD, Lindsey JC, Hughes MD, et al., Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr 2003; 33:56-65.
20. de Martino M, Tovo PA, Galli L, et al. Italian Register for HIV infection in Children. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001; 15:1527-1534.
21. Guillen S, Ramos JT, Resino R, et al. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26:334-338.
22. Nachman SA, Lindsey JC, Moye J, et al., Pediatric AIDS Clinical Trials Group 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005; 24:352-357.
23. Carter RJ, Wiener J, Abrams EJ, et al., Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41:453-460.
24. Currie C, Roberts C, Morgan A, et al., editors. Young people's health in context. Health Behaviour in school-aged children. Denmark: World Health Organisation; 2004.
25. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
26. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:161-168.
27. Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Paediatric 2004; 114:e235-e242.
28. Balding J. Young people into 2006. Exeter: Schools Health Education Unit; 2006.
29. Aka Dago-Akribi H, Cacou Adjoua MC. Psychosexual development among HIV-positive adolescents in Abidjan, Cote d'Ivoire. Reprod Health Matters 2004; 12:19-28.
30. Rosso R, Vignolo M, Parodi A, et al. Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. AIDS Res Hum Retroviruses 2005; 21:927-932.
31. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718.
32. Cromer BA, Scholes D, Berenson A, et al. Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents: the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296-301.
33. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Raport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2359-2361.
34. Gaughan DM, Hughes MD, Oleske JM, et al., Pediatric AIDS Clinical Trials Group 219C Team. Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Paediatrics 2004; 113:e544-e551.
35. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection. Pediatr Infect Dis J 2006; 25:432-437.
36. Fielden SJ, Sheckter L, Chapman GE, et al. Growing up: perspectives of children, families and service providers regarding the needs of older children with perinatally-acquired HIV. AIDS Care 2006; 18:1050-1053.
37. Murphy DA, Belzer M, Durako SJ, et al., Adolescent Medicine HIV/AIDS Research Network. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005; 159:764-770.
38. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
39. Flynn M, Bret J, Douglas S, et al. Virologic and Immunologic outcomes after 24 weeks in HIV Type 1 Infected adolescents receiving HAART. JID 2004; 190:271-279.
40. Haven B, Wiener L. From adolescence through Young adulthood: Psychological adjustment associated with long term survival of HIV. J of Adolescent Health 2001; 30:161-168.
41. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to HAART: French prospective controlled study. HIC Clin Trials 2003; 4:121-131.
42. Geary MK, King G, Forsberg AD, et al. Issues of disclosure and condom use in adolescents with hemophilia and HIV. Hemophilia Behavioral Evaluative Intervention Project Staff. Pediatr AIDS HIV Infect 1996; 7:418-423.
43. Melvin D, Jungman E, Foster C, et al. Guidance on transition and long term follow up services for adolescents with HIV infection acquired in infancy (updated 2007). London: CHIVA; 2007.